"We continue to actively enroll patients in our lead clinical trial, VBP101 and look forward to sharing important initial clinical proof of concept data from this study by year end," said Dr. Robert Ang, Vor Bio’s President and CEO. "We are excited that our new in-house clinical manufacturing facility is now operational and our IND for VCAR33 is on-track for submission in the first half of 2023. We remain fully focused on our mission to transform the standard of care for patients with blood cancers." Cash, cash equivalents and investments were $136.1M as of September 30, 2022, which is anticipated to fund operations into the first quarter of 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VOR:
